Page 44 - Haematologica Vol. 109 - July 2024

REVIEW ARTICLE - Minimal residual disease in multiple myeloma R. Szalat et al.
34. Mazzotti C, Buisson L, Maheo S, et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2018;2(21):2811-2813.
35. Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20(7):404-416.
36. Jang JS, Li Y, Mitra AK, et al. Molecular signatures of multiple myeloma progression through single cell RNA-Seq. Blood Cancer J. 2019;9(1):2.
37. Ledergor G, Weiner A, Zada M, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24(12):1867-1876.
38. Shalek AK, Benson M. Single-cell analyses to tailor treatments. Sci Transl Med. 2017;9(408):eaan4730.
39. Thoren KL. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease. Semin Hematol. 2018;55(1):41-43.
40. Martins CO, Huet S, Yi SS, et al. Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma. J Mol Diagn. 2020;22(7):901-911.
41. Chapman JR, Thoren KL. Tracking of low disease burden in multiple myeloma: using mass spectrometry assays in peripheral blood. Best Pract Res Clin Haematol. 2020;33(1):101142.
42. Mills JR, Kohlhagen MC, Dasari S, et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62(10):1334-1344.
43. Barnidge DR, Dispenzieri A, Merlini G, Katzmann JA, Murray DL. Monitoring free light chains in serum using mass spectrometry. Clin Chem Lab Med. 2016;54(6):1073-1083.
44. Liyasova M, McDonald Z, Taylor P, et al. A personalized mass spectrometry-based assay to monitor M-protein in patients with multiple myeloma (EasyM). Clin Cancer Res. 2021;27(18):5028-5037.
45. Zajec M, Jacobs JFM, Groenen P, et al. Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies. J Proteome Res. 2018;17(3):1326-1333.
46. Wijnands C, Langerhorst P, Noori S, et al. M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator. Clin Chem Lab Med. 2023;62(3):540-550.
47. Derman BA, Stefka AT, Jiang K, et al. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021;11(2):19.
48. Zamagni E, Nanni C, Dozza L, et al. Standardization of (18) F-FDG-PET/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39(2):116-125.
49. Zamagni E, Tacchetti P, Barbato S, Cavo M. Role of imaging in the evaluation of minimal residual disease in multiple myeloma patients. J Clin Med. 2020;9(11):3519.
50. Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302-e312.
51. Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: How? When? Blood. 2019;133(7):644-651.
52. Cavo M, Terpos E, Nanni C, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206-e217.
53. Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911-2918.
54. Zamagni E, Nanni C, Mancuso K, et al. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21(19):4384-4390.
55. Rasche L, Alapat D, Kumar M, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019;33(7):1713-1722.
56. Davies FE, Rosenthal A, Rasche L, et al. Treatment to suppression of focal lesions on positron emission tomography- computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018;103(6):1047-1053.
57. Zamagni E, Nanni C, Gay F, et al. Impact of imaging FDG-PET/CT minimal residual disease assessment on outcomes and matching with bone marrow techniques in newly diagnosed transplant eligible multiple myeloma (MM) patients: results of the phase II randomized Forte trial. Blood.
2020;136(Suppl 1):27-28.
58. Moreau P, Zweegman S, Perrot A, et al. Evaluation of the
prognostic value of positron emission tomography-computed tomography (PET-CT) at diagnosis and follow-up in transplant- eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia study: results of the Cassiopet Companion study. Blood. 2019;134(Suppl 1):692.
59. Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130(1):30-34.
60. Pandit-Taskar N. Functional imaging methods for assessment of minimal residual disease in multiple myeloma: current status and novel immunoPET based methods. Semin Hematol. 2018;55(1):22-32.
61. Anderson KC, Auclair D, Kelloff GJ, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin Cancer Res. 2017;23(15):3980-3993.
62. Ulaner GA, Sobol NB, O’Donoghue JA, et al. CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging. Radiology. 2020;295(3):606-615.
63. Ulaner GA, Landgren CO. Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. Best Pract Res Clin Haematol. 2020;33(1):101148.
64. Hillengass J, Ayyaz S, Kilk K, et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica. 2012;97(11):1757-1760.
65. Mosebach J, Shah S, Delorme S, et al. Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica. 2018;103(2):336-343.
Haematologica | 109 July 2024
2058